Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ras-like protein family member 12 (RASL12) is a small GTPase protein featuring a characteristic GTP-binding domain and GTPase activity[3][2][5]. It is predicted to participate in nucleotide cycling within the cell, exchanging GTP for GDP and potentially acting in signaling pathways, although its specific cellular and physiological roles remain unclear[4][2][6]. RASL12 lacks the lipid modification signals typical of many membrane-associated Ras superfamily members, suggesting it may function outside membrane compartments[4]. It has been implicated in rare gastrointestinal disorders (bile acid malabsorption and diarrhea), but no definitive disease mechanisms or pharmacological interactions are reported[6]. No current evidence supports its use as a drug target, biomarker, or risk factor. Note on ambiguity: RASL12’s functions and clinical relevance are poorly characterized compared to other Ras superfamily members. It is not currently considered a receptor, enzyme, or transporter, nor a validated drug target. Most information is predictive rather than experimentally confirmed.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ras-like protein family member 12 (RASL12).